Interpace Diagnostics Group, Inc. (IDXG) Rating Reiterated by Maxim Group
Interpace Diagnostics Group, Inc. (NASDAQ:IDXG)‘s stock had its “buy” rating restated by Maxim Group in a report issued on Tuesday. They presently have a $5.00 price target on the business services provider’s stock. Maxim Group’s price objective points to a potential upside of 323.73% from the stock’s previous close.
Separately, ValuEngine upgraded Interpace Diagnostics Group from a “strong sell” rating to a “sell” rating in a research note on Monday, September 11th.
Interpace Diagnostics Group (NASDAQ IDXG) traded down $0.05 during trading on Tuesday, hitting $1.18. The company’s stock had a trading volume of 947,000 shares, compared to its average volume of 2,159,749. The company has a market cap of $33.02, a P/E ratio of 0.43 and a beta of 1.62. Interpace Diagnostics Group has a 1-year low of $0.70 and a 1-year high of $19.80.
Interpace Diagnostics Group Company Profile
Interpace Diagnostics Group, Inc, formerly PDI, Inc, is focused on developing and commercializing molecular diagnostic tests principally focused on early detection of high potential progressors to cancer and leveraging the latest technology and personalized medicine for patient diagnosis and management.
Receive News & Stock Ratings for Interpace Diagnostics Group Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Diagnostics Group Inc. and related stocks with our FREE daily email newsletter.